Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer

Bibliographic Details
Main Authors:	T Brown, A Boland, A Bagust, J Oyee, J Hockenhull, Y Dundar, R Dickson, VS Ramani, C Proudlove
Format:	Article
Language:	English
Published:	NIHR Journals Library 2010-10-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta14suppl2/10

Similar Items

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
by: T Brown, et al.
Published: (2013-07-01)

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: N Fleeman, et al.
Published: (2010-05-01)

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation
by: Janette Greenhalgh, et al.
Published: (2015-06-01)

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
by: J Greenhalgh, et al.
Published: (2010-10-01)

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
by: T Brown, et al.
Published: (2013-02-01)

Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan
by: Cheng-Ta Yang, et al.
Published: (2010-01-01)

Erlotinib for the treatment of relapsed non-small cell lung cancer
by: C McLeod, et al.
Published: (2009-06-01)

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
by: N Fleeman, et al.
Published: (2011-12-01)

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
by: Zhang L, et al.
Published: (2021-05-01)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
by: J Greenhalgh, et al.
Published: (2011-09-01)

Rituximab for the treatment of rheumatoid arthritis
by: A Bagust, et al.
Published: (2009-09-01)

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
by: Shu Yong-Qian, et al.
Published: (2010-09-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
by: Yuan Y, et al.
Published: (2014-05-01)

Gefitinib in Advanced Non-small-cell Lung Cancer
by: Zhenjun YANG, et al.
Published: (2009-05-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
by: Lin L, et al.
Published: (2016-10-01)

Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with mutations
by: Pham Van Luan, et al.
Published: (2021-02-01)

Systematic review and cost-effectiveness evaluation of ‘pill-in-the-pocket’ strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy
by: C Martin Saborido, et al.
Published: (2010-06-01)

A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
by: J Hockenhull, et al.
Published: (2012-03-01)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
by: Zhonghan Zhang, et al.
Published: (2019-12-01)

Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
by: Adolfo Favaretto, et al.
Published: (2017-08-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
by: Chien-Ming Liu, et al.
Published: (2014)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
by: Vamsidhar Velcheti, et al.
Published: (2010-04-01)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
by: Chien-Ming Liu, et al.
Published: (2015-01-01)

Perforating Corneal Ulceration in a Patient with Lung Metastatic Adenocarcinoma Treated with Gefitinib: A Case Report
by: Enjie Ibrahim, et al.
Published: (2012-01-01)

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation
by: J Hockenhull, et al.
Published: (2008-04-01)

Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
by: Mei-Chuan Tang, et al.
Published: (2015-01-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Clinical Observation of Gefitinib with Pericardial Perfusion for  Advanced Non-small Cell Lung Cancer
by: Xiaomeng WANG, et al.
Published: (2018-01-01)

Gefitinib Monotherapy in Advanced non-small-cell Lung Cancer: A Retrospective Analysis
by: S Shrestha, et al.
Published: (2012-06-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

Molecular Factors Related to Gefitinib Efficacy in Advanced Non-small Cell Lung Cancer
by: Tao ZHOU, et al.
Published: (2010-03-01)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
by: Harada Masao, et al.
Published: (2007-03-01)

Gefitinib (Iressa®) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center
by: Auro del Giglio, et al.

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)